Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications

✍ Scribed by David J. Adelstein; Vishwa M. Sharan; Catherine Damm; A. Scott Earle; Ajit C. Shah; Chandra D. Haria; Joan E. Trey; Susan G. Carter; John D. Hines

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 573 KB
• Volume: 70
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19921201)70:11<2685::aid-cncr2820701120>3.0.co;2-v

✦ Synopsis

Methods. Between 1983 and 1989,42 patients with Stage 11,111, and IV, node-negative, squamous cell head and neck cancer were treated with concurrent 5-flUOrOuracil, cisplatin, and radiation therapy. Two courses of chemotherapy with 30 Gy of concurrent radiation therapy were to be followed in all patients by definitive surgery and then an additional 30 Gy of radiation therapy and one to two courses of chemotherapy. The patients who achieved a complete response to the initial induction treatment, however, did not undergo surgery.

Results. After the completion of all therapy, 41 of the 42 patients (98%) were considered disease-free. Only 4 of these 41 had relapses, for a projected Kaplan-Meier disease-free survival rate of 86%. Treatment failure occurred in no patients with Stage 11,1 of 17 patients with Stage 111, and 4 of 14 patients with Stage IV disease. Of the 42 patients, 23 (55%) did not require surgery after achieving a complete response to induction therapy, and only 1 of these 23 patients subsequently had a relapse.

Conclusions. Although the value of adding chemotherapy to conventional treatment remains unproven in squamous cell head and neck cancer, this treatment schedule appears promising in node-negative disease. Randomized trials will be necessary, however, to validate the efficacy of this approach and confirm the suggestion by the authors that surgery can be avoided in most patients with NO disease. Cancer 1992; 70:2685-90.